Bleselumab
- CAS No.
- 1453067-91-8
- Chemical Name:
- Bleselumab
- Synonyms
- Bleselumab;Bleselumab (anti-CD40);Research Grade Bleselumab;Research Grade Bleselumab (DHD68902)
- CBNumber:
- CB88080949
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | AS3AZ5R46K |
Bleselumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0620824 | Bleselumab 98.97% | 1453067-91-8 | 1mg | $325 | 2026-06-04 | Buy |
| ChemScene | CS-0620824 | Bleselumab 98.97% | 1453067-91-8 | 5mg | $845 | 2026-06-04 | Buy |
| ChemScene | CS-0620824 | Bleselumab 98.97% | 1453067-91-8 | 10mg | $1354 | 2026-06-04 | Buy |
| aablocks | AA02AP4U | Bleselumab ≥95%(SDS-PAGE&SEC-HPLC) | 1453067-91-8 | 1mg | $572 | 2026-06-02 | Buy |
| aablocks | AA02AP4U | Bleselumab ≥95%(SDS-PAGE&SEC-HPLC) | 1453067-91-8 | 5mg | $1500 | 2026-06-02 | Buy |
Bleselumab Chemical Properties, Uses, Production
Uses
Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: 0.24nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection[1].
in vivo
Bleselumab (0.1-10mg/kg, i.v.) inhibits Delayed-type hypersensitivity (DTH) reaction in cynomolgus monkeys[2].
Bleselumab (2 mg/kg, i.v.) prolongs renal allograft survival in Cynomolgus monkeys[3].
Bleselumab (2 or 5 mg/kg, i.v.) together with Tacrolimus (HY-13756) shows a longer median survival time (MST) than monotherapy[3].
| Animal Model: | Cynomolgus monkeys[2]. |
| Dosage: | 0.1, 1 and 10mg/kg |
| Administration: | Intravenous injection (i.v.) |
| Result: | Inhibited anti-TTx IgG and anti-TTx IgM productions in a concentration-dependent manner. |
References
[1] Harland RC, et al. Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study. Am J Transplant. 2020 Jan;20(1):159-171. DOI:10.1111/ajt.15591
[2] Okimura K, et al. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am J Transplant. 2014 Jun;14(6):1290-9. DOI:10.1111/ajt.12678
[3] Song L, et al. Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys. Transplantation. 2014 Aug 15;98(3):267-76. DOI:10.1097/TP.0000000000000236
Bleselumab Preparation Products And Raw materials
Raw materials
Preparation Products
Bleselumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
| Changsha Fuzhen Biotechnology Co.，LTD | 15111215862 18229892877 | 3062105966@qq.com | China | 5568 | 58 |
| Olix ( Hubei) Pharmaceutical Technology Co., Ltd | 17316404525 17316404525 | 209533805@qq.com | China | 9769 | 58 |
